Ligand–Receptor Interactions and Structure–Function Relationships in Off-Target Binding of the β3-Adrenergic Agonist Mirabegron to α1A-Adrenergic Receptors
Open Access
- 7 July 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7468
Abstract
The β3-adrenoceptor agonist mirabegron is available for the treatment of storage symptoms of overactive bladder, including frequency, urgency, and incontinence. The off-target effects of mirabegron include binding to α1-adrenoceptors, which are central in the treatment of voiding symptoms. Here, we examined the structure–function relationships in the binding of mirabegron to a cryo-electron microscopy structure of α1A. The binding was simulated by docking mirabegron to a 3D structure of a human α1A-adrenoceptor (7YMH) using Autodock Vina. The simulations identified two binding states: slope orientation involving 10 positions and horizontal binding to the receptor surface involving 4 positions. No interactions occurred with positions constituting the α1A binding pocket, including Asp-106, Ser-188, or Phe-312, despite the positioning of the phenylethanolamine moiety in transmembrane regions close to the binding pocket by contact with Phe-288, -289, and Val-107. Contact with the unique positions of α1A included the transmembrane Met-292 during slope binding and exosite Phe-86 during horizontal binding. Exosite binding in slope orientation involved contact of the anilino part, rather than the aminothiazol end, to Ile-178, Ala-103, and Asn-179. In conclusion, contact with Met-292 and Phe-86, which are unique positions of α1A, accounts for mirabegron binding to α1A. Because of its lack of interactions with the binding pocket, mirabegron has lower affinity compared to α1A-blockers and no effects on voiding symptoms.Keywords
This publication has 44 references indexed in Scilit:
- Adrenoceptors in the Lower Urinary Tract2023
- Molecular Dynamics Simulation of Proteins2019
- Mirabegron in overactive bladder: A review of efficacy, safety, and tolerabilityNeurourology and Urodynamics, 2013
- The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trialsInternational Urology and Nephrology, 2013
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Computational studies of the binding site of α1A-adrenoceptor antagonistsJournal of Molecular Modeling, 2008
- Structure–function of α1-adrenergic receptorsBiochemical Pharmacology, 2007
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005
- Modelling the Interaction of Catecholamines with the α1A Adrenoceptor Towards a Ligand-induced Receptor StructureJournal of Computer-Aided Molecular Design, 2005
- Computational development of an α1A-adrenoceptor model in a membrane mimicBiochemical and Biophysical Research Communications, 2004